Skip to main content
KOMIPHARM INTERNATIONAL CO., LTD. logo

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 326 across all filing types
Latest filing 2024-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Komipharm's 52nd General Meeting. It contains the meeting agenda, voting procedures, electronic voting instructions, and detailed management reports (business overview, market analysis, and financial information) required for shareholders to make informed decisions. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI), which provides shareholders with the necessary information to vote on agenda items.
2024-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It includes details on the meeting date, agenda items (such as approval of financial statements), and instructions for electronic voting. While it contains financial data, the primary purpose is proxy solicitation for the AGM, making it a Proxy Solicitation & Information Statement.
2024-03-13 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Kormipharm. It outlines the date, location, agenda items (such as financial statement approval, director appointments, and business purpose changes), and proxy-related information. This document serves as the official notification and solicitation of shareholder participation for the upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-03-11 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal announcement of a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) by K-MediPharm. It details the contract value, the counterparty (Public Procurement Service), the contract period, and specific terms. In the context of financial filings, announcements of specific commercial contracts that do not fit into other categories like M&A or capital changes are classified as general regulatory filings.
2024-03-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by Komipharm. It details share acquisitions (장내매수) by a director/major shareholder (Yang Kyung-hoon). This type of filing, which reports personal share transactions by company insiders, is classified as 'Director's Dealing' (DIRS).
2024-03-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a transaction (purchase) of shares by an executive (Park Yong-nam) of the company Komipharm. This is a standard insider trading disclosure, which falls under the 'Director's Dealing' category.
2024-02-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.